Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004354
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-10-18
Brief Title:
Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism
Sponsor:
National Center for Research Resources NCRR
Organization:
National Center for Research Resources NCRR
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2002-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
OBJECTIVES I Determine the prevalence of glucocorticoid-remediable aldosteronism GRA in various hypertensive populations and screen at risk members of GRA pedigrees
II Investigate other factors regulating blood pressure in GRA environmental genetically determined factors
III Investigate renal and hormonal mechanisms regulating potassium homeostasis in GRA
IV Describe clinical phenotype of GRA patients V Prospectively screen GRA-affected patients with MRI angiography for intracranial aneurysm
II Investigate other factors regulating blood pressure in GRA environmental genetically determined factors
III Investigate renal and hormonal mechanisms regulating potassium homeostasis in GRA
IV Describe clinical phenotype of GRA patients V Prospectively screen GRA-affected patients with MRI angiography for intracranial aneurysm
Detailed Description:
PROTOCOL OUTLINE
Patients are screened for high blood pressure suppressed plasma renin activity level and low potassium levels Urine is collected for a 24 hour period Blood specimen is collected for molecular biologic evaluation for the presence of the chimeric gene diagnostic of GRA Any history of cardiovascular events is recorded
Patients are screened for high blood pressure suppressed plasma renin activity level and low potassium levels Urine is collected for a 24 hour period Blood specimen is collected for molecular biologic evaluation for the presence of the chimeric gene diagnostic of GRA Any history of cardiovascular events is recorded
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| BWH-91328603 | None | None | None |